TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21937486

Group type: EXPERIMENTAL
Intervention: Thermostatic control sterilisation programme (heating water to 65°C during 00:00‐06:00 h and to 50°C from 06:00 to 00:00 h daily)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Standard control (constant temperature 65°C)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Thermostatic control sterilisation programme
Number of subjects: 150

Group type: COMPARATOR
Intervention: Standard control
Number of subjects: 150

Group type: COMPARATOR
Intervention: Gas consumption per day
Number of subjects: 150
Study: 18335154

Group type: COMPARATOR
Intervention: Bupivacaine injection into the subcutaneous and muscular layers around the incision site
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Intra‐ and perifacetal joint infiltration with bupivacaine
Number of subjects: 40
Study: 17010727

Group type: EXPERIMENTAL
Intervention: Lidocaine jelly instillation (2 mL)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control (no jelly instillation)
Number of subjects: 34
Study: 12797858

Group type: EXPERIMENTAL
Intervention: Breast awareness and prompt reporting of breast symptoms
Number of subjects: 0

Group type: COMPARATOR
Intervention: Systematic approach to breast self-examination
Number of subjects: 0
Study: 11075961

Group type: EXPERIMENTAL
Intervention: Patellar resurfacing
Number of subjects: 47

Group type: COMPARATOR
Intervention: No patellar resurfacing (Control)
Number of subjects: 47
Study: 8832268

Group type: EXPERIMENTAL
Intervention: Land-based exercise program (LBE)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Water-based exercise program (WBE)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Both LBE and WBE
Number of subjects: 41
Study: 8068604

Group type: EXPERIMENTAL
Intervention: Conventional immunoreactive insulin assay
Number of subjects: 803

Group type: EXPERIMENTAL
Intervention: Specific Linco insulin assay
Number of subjects: 803
Study: 3284270

Group type: EXPERIMENTAL
Intervention: Alcuronium 0.03 mg/kg
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Alcuronium 0.03 mg/kg (3-min group)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Alcuronium 0.03 mg/kg (2- and 3-min groups)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Control group (saline pretreatment)
Number of subjects: 78
Study: 30305044

Group type: EXPERIMENTAL
Intervention: Whole body vibration training (40 Hz, 4 mm, 360 s, for 12 weeks)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 12
Study: 28566523

Group type: EXPERIMENTAL
Intervention: Acid-stable lipid emulsion (LE1)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Acid-unstable lipid emulsion (LE4)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: OCC (13C octanoate)
Number of subjects: 50

Group type: COMPARATOR
Intervention: ACC (13C sodium acetate)
Number of subjects: 50

Group type: COMPARATOR
Intervention: MRI
Number of subjects: 50
Study: 25556156

Group type: EXPERIMENTAL
Intervention: Dual-task training (12 sessions; 60 min each; 12 weeks)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Non-training control group
Number of subjects: 38
Study: 23777480

Group type: EXPERIMENTAL
Intervention: Exercise (minimum of 150 minutes of moderate to vigorous intensity exercise per week, aiming for 240 minutes per week for 12 months)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional treatment (control group)
Number of subjects: 60
Study: 20164319

Group type: EXPERIMENTAL
Intervention: liquid yogurt with a straw
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: liquid yogurt with a spoon
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: semisolid yogurt with a spoon
Number of subjects: 105
Study: 19102186

Group type: EXPERIMENTAL
Intervention: Acupoint massage (group B)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Rotatory reduction manipulation (group A)
Number of subjects: 76
Study: 16331115

Group type: EXPERIMENTAL
Intervention: Home blood pressure monitoring (HBPM) using an OMRON electronic monitor
Number of subjects: 250

Group type: COMPARATOR
Intervention: Standard health intervention
Number of subjects: 250
Study: 14602748

Group type: EXPERIMENTAL
Intervention: NVP
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: NFV
Number of subjects: 43
Study: 10719812

Group type: EXPERIMENTAL
Intervention: General anesthesia
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Locoregional anesthesia
Number of subjects: 4
Study: 9164003

Group type: EXPERIMENTAL
Intervention: b.i.d. group: one capsule of slow‐release nicardipine, 20 mg, twice a day, three months
Number of subjects: 7274

Group type: COMPARATOR
Intervention: t.i.d. group: one tablet of regular nicardipine, 20 mg, three times a day, three months
Number of subjects: 7274
Study: 1461523

Group type: EXPERIMENTAL
Intervention: Amino acid input during TPN
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Different amino acid compositions during TPN
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Exponential regression curves
Number of subjects: 0
Study: 6237116

Group type: EXPERIMENTAL
Intervention: Flutamide (750 mg/day)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Cyproterone acetate (100 mg/day)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 30762694

Group type: EXPERIMENTAL
Intervention: Single-injection bupivacaine interscalene block with adjuvant clonidine, dexamethasone, and buprenorphine; multimodal analgesia including acetaminophen, NSAIDs, and opioids.
Number of subjects: 102
Study: 29522979

Group type: EXPERIMENTAL
Intervention: Cholecalciferol (4000 IU/d) for 3 months
Number of subjects: 13
Study: 27305512

Group type: EXPERIMENTAL
Intervention: Euclea natalensis gel
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group (no gel applied)
Number of subjects: 10
Study: 24310343

Group type: EXPERIMENTAL
Intervention: lutein/zeaxanthin, 10 mg/2 mg
Number of subjects: 4203

Group type: EXPERIMENTAL
Intervention: lutein/zeaxanthin
Number of subjects: 4203
Study: 22290953

Group type: EXPERIMENTAL
Intervention: 200 mg TID on days 9 to 15
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: 400 mg BID on days 9 to 15
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: 400 mg TID on days 9 to 15
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: 200 mg TID on days 1 to 8
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Higher doses (400 mg BID and 400 mg TID)
Number of subjects: 75
Study: 19943055

Group type: EXPERIMENTAL
Intervention: Two-layer running suture
Number of subjects: 248

Group type: COMPARATOR
Intervention: Interrupted figure-of-eight suture
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Overall major complication rate
Number of subjects: 248
Study: 17435541

Group type: EXPERIMENTAL
Intervention: Alvimopan 6 mg
Number of subjects: 1212

Group type: EXPERIMENTAL
Intervention: Alvimopan 12 mg
Number of subjects: 1212

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1212
Study: 15751772

Group type: EXPERIMENTAL
Intervention: Nevirapine (once or twice daily)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Efavirenz
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination with lamivudine and stavudine
Number of subjects: 0
Study: 11892685

Group type: EXPERIMENTAL
Intervention: Homeopathic Arnica tablets and herbal Arnica ointment
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study: 10459957

Group type: EXPERIMENTAL
Intervention: Zidovudine 300 mg tablet twice daily from 36 weeks' gestation and every 3 h from onset of labour until delivery
Number of subjects: 397

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 397

Group type: EXPERIMENTAL
Intervention: Zidovudine
Number of subjects: 397
Study: 7887759

Group type: EXPERIMENTAL
Intervention: Small-group consensus process intervention (1 hour meeting with expert presentation and structured discussion)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Control group (unrelated discussion on non-steroidal drug use)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Prequestionnaires and postquestionnaires measuring influenza knowledge and prevention attitudes
Number of subjects: 65
Study: 2242520

Group type: EXPERIMENTAL
Intervention: Nicardipine 30 mg three times daily
Number of subjects: 383

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 383
Study: 111886

Group type: EXPERIMENTAL
Intervention: Low-dose continuous intravenous insulin infusion
Number of subjects: 58

Group type: COMPARATOR
Intervention: High-dose intermittent subcutaneous injections
Number of subjects: 58
Study: 31669447

Group type: EXPERIMENTAL
Intervention: Vitamin D3 (2000 IU/day)
Number of subjects: 15804

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15804
Study: 28049481

Group type: EXPERIMENTAL
Intervention: RDTs introduced in ADDOs
Number of subjects: 310

Group type: COMPARATOR
Intervention: Control district (no RDTs introduced)
Number of subjects: 310
Study: 25801095

Group type: EXPERIMENTAL
Intervention: Intravenous peginterferon alfa-2a 180 μg, once weekly for 2 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intravenous peginterferon alfa-2a 180 μg, twice weekly for 2 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Subcutaneous peginterferon alfa-2a 180 μg, once weekly for 2 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Subcutaneous peginterferon alfa-2a 180 μg, twice weekly for 2 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intravenous administration
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All treatment arms
Number of subjects: 0
Study: 23680627

Group type: EXPERIMENTAL
Intervention: Visumax femtosecond platform (Group 1)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Intralase femtosecond platform (Group 2)
Number of subjects: 45
Study: 21869697

Group type: EXPERIMENTAL
Intervention: Citalopram
Number of subjects: 51

Group type: COMPARATOR
Intervention: Sertraline
Number of subjects: 51
Study: 19630974

Group type: EXPERIMENTAL
Intervention: Continuation of donepezil with memantine placebo added
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: Switch to memantine with donepezil placebo added
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: Donepezil and memantine together
Number of subjects: 800

Group type: COMPARATOR
Intervention: Donepezil placebo with memantine placebo
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: Secondary outcomes
Number of subjects: 800
Study: 16713391

Group type: EXPERIMENTAL
Intervention: 20 g of industrially produced TFA (IP‐TFA)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: 4 g n‐3 PUFA
Number of subjects: 87

Group type: COMPARATOR
Intervention: Control fat
Number of subjects: 87
Study: 15295409

Group type: EXPERIMENTAL
Intervention: Stress Tc-99m sestamibi lung uptake
Number of subjects: 192
Study: 11425821

Group type: EXPERIMENTAL
Intervention: 3.75 mg injection of triptorelin (group 1)
Number of subjects: 132

Group type: COMPARATOR
Intervention: 100 microg triptorelin daily reduced to 50 microg at the start of FSH stimulation (group 2)
Number of subjects: 132
Study: 9250557

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 50

Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 50
Study: 8102890

Group type: EXPERIMENTAL
Intervention: Axillary dissection (n=100)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Axillary biopsy (n=100)
Number of subjects: 200
Study: 3304156

Group type: EXPERIMENTAL
Intervention: Intravenous ampicillin
Number of subjects: 107

Group type: COMPARATOR
Intervention: Cefamandole
Number of subjects: 107
Study: 29499859

Group type: EXPERIMENTAL
Intervention: TRANSTAR operation
Number of subjects: 208

Group type: COMPARATOR
Intervention: Double TST36 staplers
Number of subjects: 208
Study: 27711918

Group type: EXPERIMENTAL
Intervention: Aflibercept (2.0 mg)
Number of subjects: 660

Group type: COMPARATOR
Intervention: Bevacizumab (1.25 mg)
Number of subjects: 660

Group type: COMPARATOR
Intervention: Ranibizumab (0.3 mg)
Number of subjects: 660

Group type: EXPERIMENTAL
Intervention: Bevacizumab with laser treatment
Number of subjects: 660
Study: 24635756

Group type: EXPERIMENTAL
Intervention: Low ventilatory capacity (forced expiratory volume in 1 second less than lower limit of normal)
Number of subjects: 1635

Group type: EXPERIMENTAL
Intervention: Respiratory muscle weakness (maximal inspiratory pressure < lower limit of normal)
Number of subjects: 1635

Group type: EXPERIMENTAL
Intervention: Dyspnea (moderate to severe ratings on the modified Borg index after a 400-m walk test)
Number of subjects: 1635

Group type: EXPERIMENTAL
Intervention: Moderate to severe mobility impairment (Short Physical Performance Battery score ≤ 7)
Number of subjects: 1635

Group type: EXPERIMENTAL
Intervention: Slow gait speed (400-MWT gait speed <0.8 m/s)
Number of subjects: 1635

Group type: EXPERIMENTAL
Intervention: Low ventilatory capacity
Number of subjects: 1635

Group type: EXPERIMENTAL
Intervention: Respiratory muscle weakness
Number of subjects: 1635

Group type: EXPERIMENTAL
Intervention: Dyspnea
Number of subjects: 1635
Study: 21706324

Group type: EXPERIMENTAL
Intervention: Cisplatin 25 mg/m² intravenously on days 1-3 and gemcitabine 1,000 mg/m² on days 1 and 8, every 3 weeks for two cycles as neoadjuvant chemotherapy, followed by two cycles as adjuvant chemotherapy after radiotherapy.
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Intensity-modulated radiation therapy (IMRT)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Cisplatin plus gemcitabine chemotherapy and intensity-modulated radiotherapy
Number of subjects: 54
Study: 20167174

Group type: EXPERIMENTAL
Intervention: Paradigm Veo insulin pump with new calibration algorithm
Number of subjects: 72

Group type: COMPARATOR
Intervention: Paradigm REAL-Time (PRT) sensor-augmented pump system
Number of subjects: 72
Study: 18175748

Group type: EXPERIMENTAL
Intervention: 1 g vitamin C daily supplementation in humans
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 0.24 mg/cm2 body surface area vitamin C daily supplementation in rats
Number of subjects: 14
Study: 17015053

Group type: EXPERIMENTAL
Intervention: Pravastatin (40 mg)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Fluvastatin (40 mg)
Number of subjects: 32
Study: 15495678

Group type: EXPERIMENTAL
Intervention: Community-based program for reducing cardiovascular risk factors, including general CV health classes and follow-up phone calls.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group with limited follow-up.
Number of subjects: 0
Study: 10868718

Group type: EXPERIMENTAL
Intervention: Transfer of training approach
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Functional approach
Number of subjects: 80
Study: 9035634

Group type: EXPERIMENTAL
Intervention: Confidential conversations (experimental group)
Number of subjects: 186

Group type: COMPARATOR
Intervention: Control group 1 (conversations during both measurements)
Number of subjects: 186

Group type: COMPARATOR
Intervention: Control group 2 (no conversations during either measurement)
Number of subjects: 186
Study: 1551955

Group type: EXPERIMENTAL
Intervention: Cyclofenil
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 2859523

Group type: EXPERIMENTAL
Intervention: Postoperative radiation therapy (4000 or 4800 rad)
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: Postoperative chemotherapy (fluorouracil and semustine [methyl‐CCNU])
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: Combination of radiation therapy and chemotherapy
Number of subjects: 227

Group type: COMPARATOR
Intervention: No adjuvant therapy (control group)
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: Combined radiation and chemotherapy
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 227
Study: 31504395

Group type: EXPERIMENTAL
Intervention: Twin Block
Number of subjects: 100

Group type: COMPARATOR
Intervention: Dynamax
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 100
Study: 28857683

Group type: EXPERIMENTAL
Intervention: Health Promoting Lifestyle Profile 2 (HPLP2)
Number of subjects: 1200

Group type: EXPERIMENTAL
Intervention: Responsibility, interpersonal relations, and stress management (dimensions of HPLP2)
Number of subjects: 1200
Study: 25348047

Group type: EXPERIMENTAL
Intervention: Blood glycaemic control optimization programme (BGCOP)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Conventional intensive insulin therapy (CIIT)
Number of subjects: 86
Study: 24510314

Group type: EXPERIMENTAL
Intervention: Hepatic intra-arterial fotemustine (HIA) at 100 mg/m² on days 1, 8, 15 (and 22 in HIA arm only) as induction, and after a 5-week rest period every 3 weeks as maintenance.
Number of subjects: 171

Group type: COMPARATOR
Intervention: Intravenous fotemustine (IV) at 100 mg/m² on days 1, 8, 15 as induction, and after a 5-week rest period every 3 weeks as maintenance.
Number of subjects: 171
Study: 22300292

Group type: EXPERIMENTAL
Intervention: Retinal regeneration therapy laser
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control laser (photocoagulation)
Number of subjects: 35
Study: 20597707

Group type: EXPERIMENTAL
Intervention: Massage therapy
Number of subjects: 380
Study: 18757963

Group type: EXPERIMENTAL
Intervention: Bridging external fixation with supplementary Kirschner-wire fixation
Number of subjects: 88

Group type: COMPARATOR
Intervention: Volar-locked plating with screws
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 88
Study: 15956273

Group type: EXPERIMENTAL
Intervention: Galantamine (16 mg, 24 mg, or 32 mg daily)
Number of subjects: 2033

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2033
Study: 12031821

Group type: EXPERIMENTAL
Intervention: Atorvastatin (20 mg/day)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Simvastatin (20 mg/day)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Both statins
Number of subjects: 58
Study: 10406624

Group type: EXPERIMENTAL
Intervention: Laser treatment
Number of subjects: 351

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 351
Study: 8602474

Group type: EXPERIMENTAL
Intervention: Palpation over the facet joints in the cervical spine
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Test of the formina intervertebralia
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Upper limb tension test
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Neck rotation test
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Active flexion/extension test
Number of subjects: 75
Study: 2169587

Group type: EXPERIMENTAL
Intervention: Induction chemotherapy with cisplatin (100 mg/m² on days 1 and 29) and vinblastine (5 mg/m² on days 1, 8, 15, 22, and 29) followed by radiation therapy (60 Gy over 6 weeks)
Number of subjects: 155

Group type: COMPARATOR
Intervention: Radiation therapy alone (60 Gy over 6 weeks)
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Induction chemotherapy with cisplatin and vinblastine
Number of subjects: 155
Study: 7315754

Group type: EXPERIMENTAL
Intervention: EMG feedback
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Taped verbal relaxation training
Number of subjects: 24

Group type: COMPARATOR
Intervention: No contact control
Number of subjects: 24
Study: 30747964

Group type: EXPERIMENTAL
Intervention: Paracetamol (acetaminophen) 1000 mg plus ibuprofen 400 mg (PCM + IBU)
Number of subjects: 556

Group type: COMPARATOR
Intervention: Paracetamol 1000 mg (PCM)
Number of subjects: 556

Group type: COMPARATOR
Intervention: Ibuprofen 400 mg (IBU)
Number of subjects: 556

Group type: COMPARATOR
Intervention: Half-strength paracetamol 500 mg plus ibuprofen 200 mg (HS-PCM + IBU)
Number of subjects: 556

Group type: COMPARATOR
Intervention: Paracetamol (PCM) alone
Number of subjects: 556

Group type: COMPARATOR
Intervention: Half-strength paracetamol plus ibuprofen (HS-PCM + IBU)
Number of subjects: 556

Group type: COMPARATOR
Intervention: Ibuprofen alone (IBU)
Number of subjects: 556

Group type: COMPARATOR
Intervention: Paracetamol alone (PCM)
Number of subjects: 556

Group type: EXPERIMENTAL
Intervention: Groups receiving ibuprofen (IBU)
Number of subjects: 556
Study: 28205056

Group type: EXPERIMENTAL
Intervention: Ivabradine
Number of subjects: 5313

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 5313

Group type: COMPARATOR
Intervention: Hospitalizations
Number of subjects: 5313
Study: 24753036

Group type: EXPERIMENTAL
Intervention: Stenting with AO stent coverage (AOC)
Number of subjects: 321

Group type: COMPARATOR
Intervention: Stenting without AO stent coverage
Number of subjects: 321

Group type: EXPERIMENTAL
Intervention: AOC group
Number of subjects: 321

Group type: EXPERIMENTAL
Intervention: AOC
Number of subjects: 321
Study: 23756409

Group type: EXPERIMENTAL
Intervention: Patient guidance during PCI (study group)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Control group (no guidance during PCI)
Number of subjects: 108
Study: 21092933

Group type: EXPERIMENTAL
Intervention: Guided self-help (GSH)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Waiting list condition (Control)
Number of subjects: 81
Study: 19999017

Group type: EXPERIMENTAL
Intervention: Salbutamol and ipratropium bromide administered by device of measured doses and space chamber
Number of subjects: 45

Group type: COMPARATOR
Intervention: Salbutamol and ipratropium bromide nebulized with supplementary oxygen
Number of subjects: 45
Study: 17339868

Group type: EXPERIMENTAL
Intervention: CYP3A5 functional allele carriers
Number of subjects: 1398

Group type: COMPARATOR
Intervention: CYP3A5 non-functional allele carriers
Number of subjects: 1398

Group type: EXPERIMENTAL
Intervention: CYP3A5 functional allele carriers (blacks)
Number of subjects: 1398

Group type: EXPERIMENTAL
Intervention: CYP3A5 functional allele carriers (Hispanics)
Number of subjects: 1398

Group type: EXPERIMENTAL
Intervention: CYP3A5 functional allele carriers (whites)
Number of subjects: 1398

Group type: EXPERIMENTAL
Intervention: CYP3A5 genotype
Number of subjects: 1398
Study: 14981346

Group type: EXPERIMENTAL
Intervention: Clopidogrel 75 mg once daily + ASA 75 mg once daily
Number of subjects: 7599

Group type: COMPARATOR
Intervention: Clopidogrel 75 mg once daily
Number of subjects: 7599
Study: 11685162

Group type: EXPERIMENTAL
Intervention: Aspirin and ticlopidine
Number of subjects: 196

Group type: COMPARATOR
Intervention: Aspirin alone
Number of subjects: 196
Study: 9511113

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (500 mg twice daily for 2 to 3 weeks)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Cefuroxime axetil (250 mg twice daily for 2 to 3 weeks)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Number of subjects: 83

Group type: COMPARATOR
Intervention: Cefuroxime axetil
Number of subjects: 83